Cancer of unknown primary site
Keywords:
cancer of unknown primary site, clinical criteria, biologic behaviour, immuno-histochemical analysis, treatment, chemotherapyAbstract
Cancers of unknown primary site constitute a
heterogeneous group having in common their
biological behaviour. They have an incidence of 2
to 3% and are more frequent in males over the age
of sixty. Generally they have a poor prognosis;
however, certain subgroups are potentially curable
and must be identified early in order to institute an
adequate therapy. The authors make a review of the
subject with the purpose of presenting a diagnostic
and therapeutic methodology that allows a practical
approach to this group of tumours.
Downloads
References
Lembersky BC, Thomas LC. Metastases of unknown primary site. Med Clin N Am 1996; 80 (1): 153-171.
Greco FA, Hainsworth JD. Cancer of unknown primary site. In: De Vita VT, Hellman S, Rosenberg SA, ed. Cancer. Principles and
practice of oncology. Philadelphia: J.B. Lippincott Co 1997: 2423-2443.
Le Chevalier T, Cvitkovic E, Caille P. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302
consecutive autopsied patients. Arch Intern Med 1988; 148: 2035-2039.
Nystrom JS, Weiner JM, Wolf RM et al. Identifying the primary site in metastatic cancer of unknown origin. JAMA 1979; 241:
-383.
Stone RM. Metastatic cancer of unknown primary site. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, ed. Harrison’s principles of
internal medicine. New York: The MacGraw-Hill Companies Inc, 1998: 614-618.
Muir C. Cancer of unknown primary site. Cancer 1995; 75 (1): 354-356.
Abbruzzese JL, Lenzi R, Raber MN et al. The biology of unknown primary tumours. Semin Oncol 1993; 20: 238.
Ayoub JP, Hess KR, Abbruzzese MC. Unknown primary tumours metastatic to liver. J Clin Oncol 1998; 16 (6): 2105-2112.
Karsell PR, Sheedy PF, O’Connell MJ. Computed tomography in search of cancer of unknown origin. JAMA 1982; 248 (3): 340-
Mc Millan JH, Levine E, Stephens RH. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown
primary site: a retrospective study. Radiology 1982; 143: 143-146.
Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM. Metastatic and histologic presentations in unknown
primary cancer. Semin Oncol 1977; 4: 53-58.
Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10: 912-922.
Azar HA, Espinoza CG, Richman AV, Saba SR, Wang T. “Undifferentiated” large cell malignancies: an ultrastructural and
immunocytochemical study. Hum Pathol 1982; 13: 323-333.
Hainsworth JD, Wright EP, Johnson DH, Davis BW, Greco FA. Poorly differentiated carcinoma of unknown primary site: clinical
usefulness of immunoperoxidase staining. J Clin Oncol 1991; 9:1931-1938.
Hales SA, Gatter KC, Heryet A, Masur DY. The value of immunocytochemistry in differentiating high-grade lymphoma
from other anaplastic tumours: a study of anaplastic tumours from 1940 to 1960. Leuk Lymphoma 1989; 1: 59-63.
Warnke RA, Gatter KC, Falini B, et al. Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N Engl J
Med 1983; 309: 1275-1281.
Allhoff EP, Proppe KH, Chapman CM, Lin CW, Prout GR Jr. Evaluation of prostate specific acid phosphatase and prostate
specific antigen in identification of prostatic cancer. J Urol 1983; 129: 315-318.
Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993; 329 (4): 257-263.
Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site: a newly
recognised clinicopathologic entity. Ann Inter Med 1988; 109: 364-371.
Bosl GJ, Dmitrovsky E, Reuter V, Samaniego F, Murty VVVS, Chaganti RSK. A specific karyotypic abnormality in germ cell
tumours. (abst). Proc Am Soc Clin Oncol 1989; 8: 131.
Turc-Carel C, Philip I, Berger MP, Philip T, Lenoir GM. Chromosomal translocations in Ewing’s sarcoma. N Engl J Med
; 309: 497-498
Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglas EC, Israel MA. Chromosome translocation in peripheral neuroepithelioma.
N Engl J Med 1984; 311: 584-585.
Stewart JF, Tattersall MHN, Woods RL, Fox RM. Unknown primary adenocarcinoma: incidence of over investigation and
natural history. Br Med J 1979; 1: 1530-1533.
Bhatia SK, Saclarides TJ, Witt TR, Bonomi PD, Anderson KM, Economou SG. Hormone receptor studies in axillary metastases
from occult breast cancer. Cancer 1987; 59: 1170-1172.
Medini E, Medini AM, Lee CKK, Gapany M, Levitt SH. The management of metastatic squamous cell carcinoma in cervical
lymph nodes from an unknown primary. Am J Clin Oncol 1998; 21 (2): 121-125.
De Braud F, Al-Sarraf M. Diagnosis and management of squamous cell carcinoma of unknown primary tumour site of the neck.
Semin Oncol 1993; 20: 273-278.
Abbruzzese JL, Abbruzzese MC, Lenzi R et al. Analysis of a diagnostic strategy for patients presenting with tumours of
unknown origin. J Clin Oncol 1995; 13: 2094-2103.
Dalrymple JC, Bannatyne P, Russel P, et al. Extraovarian peritoneal serous papillary carcinoma: a clinicopathologic study
of 31 cases. Cancer 1989; 64: 110-115.
Hochster H, Wernz JC, Muggia FM. Intra-abdominal carcino-matosis with histologically normal ovaries. Cancer Treat Rep 1984; 68: 931-932.
Chen KT, Flam MS. Peritoneal papillary serous carcinoma with long-term survival. Cancer 1986; 58: 1371-1373.
Strnad CM, Grosh WW, Baxter J, et al. Peritoneal carcinomatosis of unknown primary site in women: a distinctive subset of adenocarcinoma. Ann Intern Med 1989; 111: 213-217.
Ransom DT, Patel SR, Keeney GL, Malkasian GD, Edmonson JH. Papillary serous carcinoma of the peritoneum: a review of 33
cases treated with platin-based chemotherapy. Cancer 1990; 66: 1091-1094.
Patel J, Nemoto T, Rosner D, Dao TL, Pickren JW. Axillary lymph node metastases from an occult breast cancer. Cancer 1981;
: 2923-2927.
Rosen PP. Axillary lymph node metastases in patients with occult non-invasive breast carcinoma. Cancer 1980; 46: 1298-1306.
Milliken ST, Tattersall MHN, Woods RL, et al. Metastatic adenocarcinoma of unknown primary site: a randomised study of
two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987; 23: 1645.
Van der Gaast A, Verweij J, Planting AST et al. 5-Fluorouracil, doxorubicin and mitomycin-C (FAM) combination chemotherapy
for metastatic adenocarcinoma of unknown primary. Eur J Cancer Clin Oncol 1988; 24: 765.
Weir L, Keane T, Cummings B et al. Radiation treatment of cervical lymph node metastases from an unknown primary: an
analysis of outcome by treatment volume and other prognostic factors. Rad Oncol 1995; 35: 206-211.
Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordoñez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly
differentiated adenocarcinoma of unknown origin: favourable subsets of patients with unknown primary carcinoma? J Clin Oncol
; 15 (5): 2056-2066
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
